Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

Adds proprietary CAR sequence IP to Liberate’s selective in vivo delivery platform, strengthening the foundation of its emerging CAR-M therapeutic class Liberate Bio, Inc., a biotechnology company ...

Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial ...

Researchers from North Carolina State University (NC State) and the University of North Carolina (UNC) at Chapel Hill have developed a “bioinstructive” implantable scaffold that manufactures and ...

A novel immunotherapy strategy that generates transient engineered chimeric antigen receptor (CAR) T cells in vivo can reduce fibrosis and restore cardiac function in a mouse model of heart failure, ...

CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and ...

Phase I clinical trial of NEO-201, an anti-tumor-associated CEACAM-5/6 monoclonal antibody in solid tumors. A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects ...

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard's lead asset AT-108 into Phase 1 clinical development -- AT-108 is a transformative immunotherapy that ...

LOS ANGELES and NIMES, France, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biotechnology company leveraging its proprietary targeted peptide delivery technology (PEP-NP™) to advance in vivo ...